Good
Partially Aligned
Patient Risk:
Low
Summary
Most clinical/mechanism and key safety/adverse event claims are supported by the provided FDA label excerpts, including the insomnia indication, sleep-onset latency efficacy, and common adverse events. Several mechanistic/biological localization and patent/generic availability statements are not supported by the provided label and should be treated as unsupported. One claim about dependence/withdrawal associated with GABA-acting drugs is not supported by the provided label excerpts.
Category Scores
Accurate Statements
Ramelteon is the generic name for the prescription sleep medication sold under the brand name Rozerem.
Not supported by the provided label excerpts (no section provided stating generic/brand relationship).
Ramelteon is used to treat insomnia characterized by difficulty with sleep onset.
INDICATIONS AND USAGE: “ROZEREM is indicated for the treatment of insomnia characterized by difficulty with sleep onset.”
Ramelteon targets melatonin receptors MT1 and MT2.
12 CLINICAL PHARMACOLOGY: “Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors …”
Melatonin receptors MT1 and MT2 are involved in regulating the sleep-wake cycle.
Not supported by the provided label excerpts (no statement provided tying MT1/MT2 to sleep-wake cycle regulation).
Ramelteon mimics the action of melatonin.
Partially supported: label describes “melatonin receptor agonist” (12.1), but the exact phrasing “mimics the action of melatonin” is not explicitly stated in provided excerpts.
Ramelteon helps reset the body's internal clock.
Not supported by the provided label excerpts.
Ramelteon promotes sleep.
Supported implicitly by indication/therapeutic goal and mechanism: INDICATIONS (insomnia treatment), 7.2 “Since the intended effect of ROZEREM is to promote sleep…”
Ramelteon is distinct from other sleep medications that act on GABA receptors.
Not supported by the provided label excerpts (no comparison to GABA-acting drugs).
Common side effects of ramelteon include fatigue.
6.1: “The most frequent adverse events… were somnolence, dizziness, nausea, fatigue, headache, and insomnia …”
Common side effects of ramelteon include dizziness.
6.1: “... dizziness ... fatigue ...”
Common side effects of ramelteon include nausea.
6.1: “... nausea ...”
Clinical trials have demonstrated ramelteon's effectiveness in improving sleep onset latency in adults with chronic insomnia.
INDICATIONS/14: 14.1 states effectiveness in sleep initiation and “reduced average latency to persistent sleep …” and adults with chronic insomnia “ROZEREM reduced sleep latency at each time point when compared to placebo.”
Studies showed statistically significant reductions in the time it takes patients to fall asleep compared to placebo.
Partially supported: 14.1 says ROZEREM reduced latency vs placebo; the provided excerpts do not explicitly state “statistically significant.”
Unsupported Statements
Ramelteon is the generic name for the prescription sleep medication sold under the brand name Rozerem.
No provided label excerpt states “generic name” or brand/generic equivalence.
Melatonin receptors MT1 and MT2 are involved in regulating the sleep-wake cycle.
No provided label excerpt links MT1/MT2 to sleep-wake cycle regulation.
Ramelteon mimics the action of melatonin.
Label calls ramelteon a “melatonin receptor agonist,” but does not explicitly use the “mimics the action of melatonin” wording in provided excerpts.
Ramelteon binds to MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) of the hypothalamus.
No provided label excerpt specifies SCN/hypothalamus localization or binding site.
Ramelteon helps reset the body's internal clock.
No provided label excerpt states “reset” of internal clock.
Ramelteon is distinct from other sleep medications that act on GABA receptors.
No provided label excerpt contrasts ramelteon with GABA-acting drugs.
The patent for ramelteon has expired.
No provided label excerpt addresses patent status.
Patents related to ramelteon have lapsed, allowing for the development of generic versions.
No provided label excerpt addresses patents or generic development.
Generic versions of ramelteon are available.
No provided label excerpt addresses availability of generics.
With the expiration of its primary patents, multiple manufacturers can produce and market generic ramelteon.
No provided label excerpt addresses manufacturers/marketing of generics.
Generic ramelteon potentially leads to lower costs for consumers.
No provided label excerpt addresses pricing or cost outcomes.
Ramelteon specifically targets melatonin receptors rather than enhancing the effects of GABA.
Label supports targeting melatonin receptors, but does not explicitly state “rather than enhancing effects of GABA.”
Ramelteon generally does not cause dependence or withdrawal symptoms associated with GABA-acting drugs.
No provided label excerpt discusses dependence/withdrawal in relation to GABA-acting drugs.
Studies showed statistically significant reductions in the time it takes patients to fall asleep compared to placebo.
Provided excerpts show reductions vs placebo but do not explicitly state “statistically significant.”
Contradictions
Important Omissions
No claims provided regarding contraindication with fluvoxamine, despite the label containing a specific contraindication.
Importance:
Low
No claims provided regarding dosage timing/meal restriction (e.g., within 30 minutes of going to bed; not with or immediately after a high-fat meal) and maximum daily dose (8 mg/day).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported mechanistic localization and patent/generic/cost assertions do not directly alter dosing or contraindication claims. However, the claim about lack of dependence/withdrawal is not supported by provided label excerpts; additionally, missing dosing/administration details could be material if used for clinical decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several statements (SCN/hypothalamus binding, internal clock reset, generic/patent availability/cost, and dependence/withdrawal comparison) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit statements to what is explicitly supported in the provided label sections: indication, melatonin MT1/MT2 agonism (without specific SCN localization), and supported adverse events/efficacy versus placebo. Remove or rephrase unsupported patent/generic availability and dependence/withdrawal assertions unless additional FDA label excerpts are provided.